Medical Dialogues
  • Dermatology
Login Register
This site is intended for healthcare professionals only
Login Register
  • MD Brand Connect
  • Vaccine Hub
  • MDTV
    • Breaking News
    • Medical News Today
    • Health News Today
    • Latest
    • Journal Club
    • Medico Legal Update
    • Latest Webinars
    • MD Shorts
    • Health Dialogues
  • Fact Check
  • Health Dialogues
Medical Dialogues
  • Medical News & Guidelines
      • Anesthesiology
      • Cardiology and CTVS
      • Critical Care
      • Dentistry
      • Dermatology
      • Diabetes and Endocrinology
      • ENT
      • Gastroenterology
      • Medicine
      • Nephrology
      • Neurology
      • Obstretics-Gynaecology
      • Oncology
      • Ophthalmology
      • Orthopaedics
      • Pediatrics-Neonatology
      • Psychiatry
      • Pulmonology
      • Radiology
      • Surgery
      • Urology
      • Laboratory Medicine
      • Diet
      • Nursing
      • Paramedical
      • Physiotherapy
  • Health news
      • Doctor News
      • Government Policies
      • Hospital & Diagnostics
      • International Health News
      • Medical Organization News
      • Medico Legal News
      • NBE News
      • NMC News
  • Fact Check
      • Bone Health Fact Check
      • Brain Health Fact Check
      • Cancer Related Fact Check
      • Child Care Fact Check
      • Dental and oral health fact check
      • Diabetes and metabolic health fact check
      • Diet and Nutrition Fact Check
      • Eye and ENT Care Fact Check
      • Fitness fact check
      • Gut health fact check
      • Heart health fact check
      • Kidney health fact check
      • Medical education fact check
      • Men's health fact check
      • Respiratory fact check
      • Skin and hair care fact check
      • Vaccine and Immunization fact check
      • Women's health fact check
  • AYUSH
    • Ayurveda
    • Homeopathy
    • Siddha
    • Unani
    • Yoga
  • State News
      • Andaman and Nicobar Islands
      • Andhra Pradesh
      • Arunachal Pradesh
      • Assam
      • Bihar
      • Chandigarh
      • Chattisgarh
      • Dadra and Nagar Haveli
      • Daman and Diu
      • Delhi
      • Goa
      • Gujarat
      • Haryana
      • Himachal Pradesh
      • Jammu & Kashmir
      • Jharkhand
      • Karnataka
      • Kerala
      • Ladakh
      • Lakshadweep
      • Madhya Pradesh
      • Maharashtra
      • Manipur
      • Meghalaya
      • Mizoram
      • Nagaland
      • Odisha
      • Puducherry
      • Punjab
      • Rajasthan
      • Sikkim
      • Tamil Nadu
      • Telangana
      • Tripura
      • Uttar Pradesh
      • Uttrakhand
      • West Bengal
  • Medical Education
      • Ayush Education News
      • Dentistry Education News
      • Medical Admission News
      • Medical Colleges News
      • Medical Courses News
      • Medical Universities News
      • Nursing education News
      • Paramedical Education News
      • Study Abroad
  • Industry
      • Health Investment News
      • Health Startup News
      • Medical Devices News
      • Pharma News
      • Pharmacy Education News
      • Industry Perspective
  • MDTV
      • Health Dialogues MDTV
      • Health News today MDTV
      • Latest Videos MDTV
      • Latest Webinars MDTV
      • MD shorts MDTV
      • Medical News Today MDTV
      • Medico Legal Update MDTV
      • Top Videos MDTV
      • Health Perspectives MDTV
      • Journal Club MDTV
      • Medical Dialogues Show
This site is intended for healthcare professionals only
LoginRegister
Medical Dialogues
LoginRegister
  • Home
  • Medical news & Guidelines
    • Anesthesiology
    • Cardiology and CTVS
    • Critical Care
    • Dentistry
    • Dermatology
    • Diabetes and Endocrinology
    • ENT
    • Gastroenterology
    • Medicine
    • Nephrology
    • Neurology
    • Obstretics-Gynaecology
    • Oncology
    • Ophthalmology
    • Orthopaedics
    • Pediatrics-Neonatology
    • Psychiatry
    • Pulmonology
    • Radiology
    • Surgery
    • Urology
    • Laboratory Medicine
    • Diet
    • Nursing
    • Paramedical
    • Physiotherapy
  • Health news
    • Doctor News
    • Government Policies
    • Hospital & Diagnostics
    • International Health News
    • Medical Organization News
    • Medico Legal News
    • NBE News
    • NMC News
  • Fact Check
    • Bone Health Fact Check
    • Brain Health Fact Check
    • Cancer Related Fact Check
    • Child Care Fact Check
    • Dental and oral health fact check
    • Diabetes and metabolic health fact check
    • Diet and Nutrition Fact Check
    • Eye and ENT Care Fact Check
    • Fitness fact check
    • Gut health fact check
    • Heart health fact check
    • Kidney health fact check
    • Medical education fact check
    • Men's health fact check
    • Respiratory fact check
    • Skin and hair care fact check
    • Vaccine and Immunization fact check
    • Women's health fact check
  • AYUSH
    • Ayurveda
      • Ayurveda Giuidelines
      • Ayurveda News
    • Homeopathy
      • Homeopathy Guidelines
      • Homeopathy News
    • Siddha
      • Siddha Guidelines
      • Siddha News
    • Unani
      • Unani Guidelines
      • Unani News
    • Yoga
      • Yoga Guidelines
      • Yoga News
  • State News
    • Andaman and Nicobar Islands
    • Andhra Pradesh
    • Arunachal Pradesh
    • Assam
    • Bihar
    • Chandigarh
    • Chattisgarh
    • Dadra and Nagar Haveli
    • Daman and Diu
    • Delhi
    • Goa
    • Gujarat
    • Haryana
    • Himachal Pradesh
    • Jammu & Kashmir
    • Jharkhand
    • Karnataka
    • Kerala
    • Ladakh
    • Lakshadweep
    • Madhya Pradesh
    • Maharashtra
    • Manipur
    • Meghalaya
    • Mizoram
    • Nagaland
    • Odisha
    • Puducherry
    • Punjab
    • Rajasthan
    • Sikkim
    • Tamil Nadu
    • Telangana
    • Tripura
    • Uttar Pradesh
    • Uttrakhand
    • West Bengal
  • Medical Education
    • Ayush Education News
    • Dentistry Education News
    • Medical Admission News
    • Medical Colleges News
    • Medical Courses News
    • Medical Universities News
    • Nursing education News
    • Paramedical Education News
    • Study Abroad
  • Industry
    • Health Investment News
    • Health Startup News
    • Medical Devices News
    • Pharma News
      • CDSCO (Central Drugs Standard Control Organisation) News
    • Pharmacy Education News
    • Industry Perspective
  • Home
  • News
  • Industry
  • Pharma News
  • Revise Itolizumab...

Revise Itolizumab phase 3 study protocol for Covid-19: CDSCO panel tells Biocon

Medical Dialogues TeamWritten by Medical Dialogues Team Published On 13 Sept 2021 11:56 AM  |  Updated On 13 Sept 2021 11:56 AM
Revise Itolizumab phase 3 study protocol for Covid-19: CDSCO panel tells Biocon
  • facebook
  • twitter
  • linkedin
  • whatsapp
  • Telegram
  • Email

New Delhi: After reviewing Biocon's Phase III trial protocol for Itolizumab for treating Covid-19 patients, the Subject Expert Committee (SEC) functional under the Central Drug Standard Organization (CDSCO) has recommended the firm to revise the protocol and submit the revised study protocol for further assessment by the Committee.

This came after Biocon Limited presented the proposal of Phase III trial protocol no. BIO-ITOLIZ-304 Version: 1.0, dated July 21,2021.

Last year, the Medical Dialogues Team had reported that Biocon Ltd. had received the Drugs Controller General of India's (DCGI) approval to market Itolizumab (ALZUMAb®) Injection 25mg/5mL solution for emergency use in India for the treatment of cytokine release syndrome (CRS) in moderate to severe ARDS (acute respiratory distress syndrome) patients due to COVID-19.

Also Read:Biocon Itolizumab Gets DCGI Nod To Treat COVID-19 Patients

The Indian drug regulatory agency had approved itolizumab for 'restricted emergency use' in moderate to severe acute respiratory distress syndrome (ARDS) owing to COVID-19 based on the data obtained from phase II, open-label, randomised, placebo-controlled trial conducted in 30 COVID-19 patients.

Despite the fact that the DCGI had approved Itolizumab for "restricted emergency use" in infected patients, the National Task Force on COVID-19 had excluded it from clinical management protocols for treating the disease.

Itolizumab was launched in India in 2013 under the brand name ALZUMAb. Itolizumab is Biocon's second 'lab to market' novel biologic after Nimotuzumab and offers a 'best-in-class' biologic drug for acute psoriasis.

Biocon repurposed Itolizumab, an anti-CD6 IgG1 monoclonal antibody for treating chronic plaque psoriasis, for the treatment of cytokine release syndrome (CRS) in moderate to severe acute respiratory distress syndrome (ARDS) patients due to COVID-19.

Itolizumab is a monoclonal antibody directed against CD6, a surface glycoprotein found on mature T cells, immature B cells, the B1a subset of B lymphocytes, and certain regions of the brain. By inhibiting CD6, itolizumab downregulates the synthesis of proinflammatory cytokines and adhesion molecules that eventually leads to reduced interferon-γ (IFNγ), interleukin (IL)-6, and tumour necrosis factor-α (TNFα) levels, along with reduced T-cell infiltration at the inflammatory sites. The potential utility of itolizumab in COVID-19, based on its unique mechanism of action in ameliorating cytokine release syndrome (CRS).

The SEC committee at its 178th meeting to examine COVID-19 related proposals under the accelerated approval process, held on 26.08.2021 and 27.08.2021 at CDSCO, thoroughly examined Biocon Limited's proposal for Phase III trial protocol no. BIO-ITOLIZ-304 Version: 1.0, dated July 21,2021.

After detailed deliberation, the committee recommended that the firm should revise the protocol with the following changes:

1) The "Adaptive" word should be removed from the proposed study protocol title.

2) Age group should be 18 to 65 years under the inclusion criteria.

3) For exclusion of TB subjects, three times TB gold (IGRA) test and one time TB PCR test with uniform lab method to be carried out.

4) Criteria for hospital discharge should be defined in the protocol.

5) There should be no re-dosing of the IMP, accordingly re-dosing of 0.8mg/kg should be removed from the proposed study protocol.

6) The interim analysis should be done once after 50% of total proposed subjects recruitment with 28days of treatment.

7) Clinical trial sites should be geographically distributed across the Country.

8) SoC should be uniform as per ICMR/GoI guideline at all participating sites and it should be recorded in CRF.

9) HRCT should be done for diagnosis of pulmonary fibrosis at screening/baseline and end of the treatment for the patients enrolled with chronic lung disease.

Furthermore, the committee directed the firm to submit a revised study protocol for further review by the committee.

Also Read: Setback To Biocon: Health Ministry Says NO To Psoriasis Drug Itolizumab In Clinical Management Protocols For COVID-19
itolizumabbioconsec committeecdscocovid19
Medical Dialogues Team
Medical Dialogues Team
    Show Full Article
    Next Story

    Editorial

    First Indian Consensus on Managing Refractory Gastroesophageal Reflux Disease Recommends Vonoprazan

    First Indian Consensus on Managing Refractory Gastroesophageal Reflux Disease Recommends Vonoprazan

    Re-visiting the Role of Pneumococcal Vaccination in Patients with Cardiovascular Diseases

    Re-visiting the Role of Pneumococcal Vaccination in Patients with Cardiovascular Diseases

    Prediabetes and the Mind: Unraveling Cognitive and Mental Health Risks

    Prediabetes and the Mind: Unraveling Cognitive and Mental Health Risks

    Real-World Case study: Darbepoetin Alfa for Chemotherapy-Induced Anemia in Metastatic Breast Cancer - Dr Aditya Murali

    Real-World Case study: Darbepoetin Alfa for Chemotherapy-Induced Anemia in Metastatic Breast Cancer...

    Aspirin in Primary Prevention- When to Consider?

    Aspirin in Primary Prevention- When to Consider?

    View All

    Journal Club Today

    Is Fitness Overrated? Study Questions the True Impact of Fitness on Early Death

    Is Fitness Overrated? Study Questions the True Impact of Fitness on Early Death

    View All

    Health News Today

    Health Bulletin 17/ May/ 2025

    Health Bulletin 17/ May/ 2025

    View All
    © 2022 All Rights Reserved.
    Powered By: Hocalwire
    X
    We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok